Votrient Gains Indication for Soft Tissue Sarcoma

Share this article:
VOTRIENT (pazopanib) 200mg, 400mg tablets by GlaxoSmithKline
VOTRIENT (pazopanib) 200mg, 400mg tablets by GlaxoSmithKline

GlaxoSmithKline announced that the FDA has approved Votrient (pazopanib) 200mg tablets for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The US label contains the following limitations: The efficacy of Votrient for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.

The approval for Votrient is based on the results a randomized, double-blind, placebo-controlled, multi-center Phase III study called PALETTE (PAzopanib ExpLorEd in sofT Tissue sarcoma).  The primary endpoint of progression-free survival per independent review was significantly prolonged with pazopanib (median: 20 vs. 7 weeks; HR=0.31, 95% CI 0.24-0.4; P<0.0001).

Votrient, a kinase inhibitor, is already indicated for the treatment of advanced renal cell carcinoma in adults.

For more information call (888) 593-5977 or visit www.gsk.com.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs